In liver cancers, including HCC and cholangiocarcinoma, MAT1A expression and activity has been found to be reduced [61] correlating with depletion of SAMe levels, promoter methylation status and, also, associates with MAT2A induction [121,239]. This evidence concerns the gene MAT2A and liver cancer.